Filtered By:
Education: Study
Nutrition: Vitamins

This page shows you your search results in order of relevance. This is page number 20.

Order by Relevance | Date

Total 2114 results found since Jan 2013.

Therapeutic treatment with ascorbate rescues mice from heat stroke-induced death by attenuating systemic inflammatory response and hypothalamic neuronal damage.
This study was performed by using the characteristic high lethality rate and sepsis-mimic systemic inflammatory response of a murine model of heat stroke to test our hypothesis that supra-physiological doses of ascorbate may have therapeutic use in critical care. We demonstrated that parenteral administration of ascorbate abrogated the lethality and thermoregulatory dysfunction in murine model of heat stroke by attenuating heat stroke-induced accelerated systemic inflammatory, coagulation responses and the resultant multiple organ injury, especially in hypothalamus. Overall, our findings support the hypothesis and notion t...
Source: Free Radical Biology and Medicine - December 15, 2015 Category: Biology Authors: Chang CY, Chen JY, Chen SH, Cheng TJ, Lin MT, Hu ML Tags: Free Radic Biol Med Source Type: research

Mp6: homocysteine level in pfo related stroke patients with respect to medical therapy vs pfo closure
Conclusions We found that compared with routine medical therapy, PFO closure reduced tHcy level in patients with mild hyperhomocysteinemia. Since PFO stroke patients tend to be younger, the life-time risk of even mildly elevated tHcy may be important for future thrombotic risk. Understanding the mechanism of PFO-related tHcy changes is important in optimizing medical treatment (e.g, folate replacement); studies are ongoing. Abstract MP6 Figure 1
Source: Journal of Investigative Medicine - February 25, 2016 Category: Research Authors: Deng, W., Wickham, T., McMullin, D., Feeney, K., Silverman, S., Inglessis, I., Palacios, I., Lo, E., Buonanno, F., Ning, M. Tags: Moderated Poster, 11:45 PM - 1:05 PM, Wednesday, April 13, 2016 Source Type: research

XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation
Conclusion XANTUS is the first international, prospective, observational study to describe the use of rivaroxaban in a broad NVAF patient population. Rates of stroke and major bleeding were low in patients receiving rivaroxaban in routine clinical practice. Trial registration number Clinicaltrials.gov: NCT01606995.
Source: European Heart Journal - April 6, 2016 Category: Cardiology Authors: Camm, A. J., Amarenco, P., Haas, S., Hess, S., Kirchhof, P., Kuhls, S., van Eickels, M., Turpie, A. G. G., the XANTUS Investigators Tags: Atrial fibrillation Source Type: research

Once-daily rivaroxaban for long-term stroke prevention in patients with atrial fibrillation
Oral anticoagulation is the long-term standard of care for preventing stroke in patients with atrial fibrillation (AF). However, anticoagulation is associated with an increased risk of bleeding, such that its use should be based on the absolute risks of stroke and bleeding, and the relative benefit–risk profile of the individual patient. Non-vitamin K antagonist oral anticoagulants, including rivaroxaban, are alternatives to vitamin K antagonists such as warfarin in this setting, and are supported in treatment guidelines as the optimal choice for patients with AF at moderate to high risk of stroke. Rivaroxaban can be...
Source: European Journal of Heart Failure Supplements - April 20, 2016 Category: Cardiology Authors: Antoniou, S., Amara, W. Tags: Articles Source Type: research

Non-Vitamin K Antagonist Oral Anticoagulants and Antiplatelet Therapy for Stroke Prevention in Patients With Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials
Non-vitamin K antagonist oral anticoagulants (NOACs) are frequently used to prevent stroke in patients with atrial fibrillation. These patients are often also on aspirin or other antiplatelet agents. It is possible that treatment with both NOACs and aspirin or other antiplatelet drug may be effective in decreasing stroke, but data are sparse regarding the efficacy and safety of using both agents for stroke prevention. To address these issues, data were pooled from the 4 recent randomized, controlled trials of NOACs: apixaban, rivaroxaban, dabigatran, and edoxaban, which included 42,411 patients; 14,148 (33.4%) were also on...
Source: Cardiology in Review - August 9, 2016 Category: Cardiology Tags: Review Articles Source Type: research

How To Lower Risk of Heart Disease and Stroke
Italy's Emma Morano will be celebrating her 117th birthday at the end of this month. She's the oldest living person in the world. And when she was asked what her secret to longevity was, she didn't miss a beat. Her answer? She eats two or three eggs every day.  I'm not at all surprised by Emma's long, healthy life. People thrived on eggs for millions of years. The Myth of Eggs and Cholesterol That is, until the 1950s, when they came under attack because they're high in cholesterol. Around that time, cholesterol was blamed for causing heart disease. And we now know that's not true. Choleste...
Source: Al Sears, MD Natural Remedies - December 15, 2016 Category: Complementary Medicine Authors: Al Sears Tags: Anti-Aging Source Type: news

Relationship Between Nutritional Factors and Hip Bone Density in Individuals with Chronic Stroke
AbstractThe aim of this study was to investigate the relationship between dietary habits and hip bone health in community-dwelling individuals with chronic stroke. The usual dietary intake of 94 individuals with chronic stroke (30 women, mean age: 59.0  years) was assessed by a 3-day food record within a single week. Dual-energy X-ray absorptiometry was used to measure bone mineral density (BMD) at both hips. The results showed that low hip bone mass was found in 59 and 50 of the participants on the affected and unaffected side, respectively. The mean hip BMD was also significantly lower on the affected side than the unaf...
Source: Calcified Tissue International - April 17, 2017 Category: Orthopaedics Source Type: research

Comment Low risk of ischaemic stroke in hyperhomocysteinaemia
Whether elevated serum homocysteine concentrations (ie, hyperhomocysteinaemia) are a risk factor for ischaemic stroke and if normalising hyperhomocysteinaemia might reduce stroke risk are controversial issues. Hyperhomocysteinaemia can be primary (ie, hereditary) or secondary (ie, due to vitamin B12 deficiency, diabetes, etc). The effect of both primary and secondary hyperhomocysteinaemia on putative stroke risk is debated. One study1 has shown that hyperhomocysteinaemia is an independent risk factor for ischaemic stroke, whereas other studies have reached different conclusions.
Source: Lancet Neurology - August 9, 2017 Category: Neurology Authors: Josef Finsterer Tags: Comment Source Type: research

B vitamins in stroke prevention: time to reconsider
Publication date: September 2017 Source:The Lancet Neurology, Volume 16, Issue 9 Author(s): J David Spence, Qilong Yi, Graeme J Hankey B vitamin therapy lowers plasma total homocysteine concentrations, and might be a beneficial intervention for stroke prevention; however, cyanocobalamin (a form of vitamin B12) can accelerate decline in renal function and increase the risk of cardiovascular events in patients with impaired renal function. Although early trials did not show benefit in reduction of stroke, these results might have been due to harm in participants with impaired renal function. In patients with diabetic nephro...
Source: The Lancet Neurology - August 9, 2017 Category: Neurology Source Type: research

Relationship between serum vitamin D levels and inflammatory markers in acute stroke patients
ConclusionsSerum vitamin D levels are inversely associated with the levels of interleukin‐6 and hsCRP, suggesting a potential anti‐inflammatory role for vitamin D in stroke individuals. Our study explored the relationship between vitamin D levels and inflammatory markers in acute stroke patients and examined the effect of vitamin D and inflammatory markers on poststroke depression. We found that serum vitamin D levels were negatively associated with serum levels of interleukin‐6, suggesting a potential anti‐inflammatory role for vitamin D. Our results provided evidence for the mechanism of poststroke depression ca...
Source: Brain and Behavior - January 11, 2018 Category: Neurology Authors: Qiongzhang Wang, Zhuoying Zhu, Yuntao Liu, Xinjie Tu, Jincai He Tags: ORIGINAL RESEARCH Source Type: research

Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study
ConclusionThis population-based cohort study of routine care indicates similar or better effectiveness and safety with NOAC compared with warfarin treatment. NOACs were associated with fewer intracranial bleeds, but more gastrointestinal bleeds.
Source: Europace - February 10, 2017 Category: Cardiology Source Type: research

Atrial Fibrillation had Less Impact on the Risk of Ischemic Stroke in Non-anticoagulated Patients Undergoing Hemodialysis: Insight from the RAKUEN study.
Conclusion A great impact on death, but not ischemic stroke, was observed in non-anticoagulated hemodialysis patients with AF in comparison to those without AF from the analysis of the RAKUEN study. PMID: 29607945 [PubMed - as supplied by publisher]
Source: Internal Medicine - April 4, 2018 Category: Internal Medicine Tags: Intern Med Source Type: research

Cerebral microbleeds and intracranial haemorrhage risk in patients anticoagulated for atrial fibrillation after acute ischaemic stroke or transient ischaemic attack (CROMIS-2): a multicentre observational cohort study
This study is registered with ClinicalTrials.gov, number NCT02513316. Findings Between Aug 4, 2011, and July 31, 2015, we recruited 1490 participants of whom follow-up data were available for 1447 (97%), over a mean period of 850 days (SD 373; 3366 patient-years). The symptomatic intracranial haemorrhage rate in patients with cerebral microbleeds was 9·8 per 1000 patient-years (95% CI 4·0–20·3) compared with 2·6 per 1000 patient-years (95% CI 1·1–5·4) in those without cerebral microbleeds (adjusted hazard ratio 3·67, 95% CI 1·27–10·60). Compared with the HAS-BLED score alone (C-index 0·41, 95% CI 0·29–0...
Source: The Lancet Neurology - May 16, 2018 Category: Neurology Source Type: research